Abstract Background Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to investigate whether dapagliflozin is able to acutely modify systemic and renal vascular function, as well as putative mechanisms. Methods Neuro-hormonal and vascular variables, together with 24 h diuresis, urinary sodium, glucose, isoprostanes and free-water clearance were assessed before and after a 2-day treatment with dapagliflozin 10 mg QD in sixteen type 2 diabetic patients; data were compared with those obtained in ten patients treated with hydrochlorothiazide 12.5 mg QD. Brachial artery endothelium-dependent and i...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2 diabetes. T...
ImportanceSodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose ex...
Endothelial dysfunction (ED) is a hallmark in type 2 diabetes mellitus (T2DM) that favor both athero...
Background: Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardi...
Background and aims: Mechanisms through which SGLT-2 inhibitors achieve cardiovascular and renal pro...
Aims: Sodium-glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tub...
Abstract Background Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors c...
Aims To assess the effect of sodium-glucose cotransporter-2 inhibitor dapagliflozin on natriuresis, ...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...
Background: Sodium glucose transporter type 2 inhibitors may reduce cardiovascular events in type 2 ...
IMPORTANCE Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose e...
CONTEXT: Mechanisms mediating the cardiovascular and renal protection exerted by SGLT2 inhibitors ar...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...
In patients with diabetes, glycemic improvement by sodium-glucose cotransporter-2 inhibition depends...
Aims Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidne...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2 diabetes. T...
ImportanceSodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose ex...
Endothelial dysfunction (ED) is a hallmark in type 2 diabetes mellitus (T2DM) that favor both athero...
Background: Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardi...
Background and aims: Mechanisms through which SGLT-2 inhibitors achieve cardiovascular and renal pro...
Aims: Sodium-glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tub...
Abstract Background Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors c...
Aims To assess the effect of sodium-glucose cotransporter-2 inhibitor dapagliflozin on natriuresis, ...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...
Background: Sodium glucose transporter type 2 inhibitors may reduce cardiovascular events in type 2 ...
IMPORTANCE Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose e...
CONTEXT: Mechanisms mediating the cardiovascular and renal protection exerted by SGLT2 inhibitors ar...
Background: Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) slow the progression of diabeti...
In patients with diabetes, glycemic improvement by sodium-glucose cotransporter-2 inhibition depends...
Aims Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidne...
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2 diabetes. T...
ImportanceSodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose ex...
Endothelial dysfunction (ED) is a hallmark in type 2 diabetes mellitus (T2DM) that favor both athero...